<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="iso-abbrev">Antimicrob. Agents Chemother</journal-id><journal-id journal-id-type="hwp">aac</journal-id><journal-id journal-id-type="pmc">aac</journal-id><journal-id journal-id-type="publisher-id">AAC</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology</publisher-name><publisher-loc>1752 N St., N.W., Washington, DC</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5923093</article-id><article-id pub-id-type="pmid">29483126</article-id><article-id pub-id-type="publisher-id">02360-17</article-id><article-id pub-id-type="doi">10.1128/AAC.02360-17</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Therapeutics</subject></subj-group></article-categories><title-group><article-title>The Clarithromycin Susceptibility Genotype Affects the Treatment Outcome of Patients with <named-content content-type="genus-species">Mycobacterium abscessus</named-content> Lung Disease</article-title><alt-title alt-title-type="running-head"><named-content content-type="genus-species">M. abscessus</named-content> Genotype, Lung Disease, and Treatment</alt-title><alt-title alt-title-type="short-authors">Guo et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Qi</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chu</surname><given-names>Haiqing</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ye</surname><given-names>Meiping</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Zhemin</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Bing</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Shiyi</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Fangyou</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><aff id="aff1"><label>a</label>Tongji University School of Medicine, Shanghai, China</aff><aff id="aff2"><label>b</label>Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China</aff><aff id="aff3"><label>c</label>State Key Laboratory of Microbial Metabolism, and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China</aff><aff id="aff4"><label>d</label>Department of Clinical Laboratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China</aff><aff id="aff5"><label>e</label>Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China</aff></contrib-group><author-notes><corresp id="cor1">Address correspondence to Haiqing Chu, <email>chu_haiqing@126.com</email>, or Meiping Ye, <email>yemeiping1988@163.com</email>.</corresp><fn fn-type="other"><p><bold>Citation</bold> Guo Q, Chu H, Ye M, Zhang Z, Li B, Yang S, Ma W, Yu F. 2018. The clarithromycin susceptibility genotype affects the treatment outcome of patients with <named-content content-type="genus-species">Mycobacterium abscessus</named-content> lung disease. Antimicrob Agents Chemother 62:e02360-17. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.02360-17">https://doi.org/10.1128/AAC.02360-17</ext-link>.</p></fn></author-notes><pub-date pub-type="epreprint"><day>26</day><month>2</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>26</day><month>4</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>4</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>62</volume><issue>5</issue><elocation-id>e02360-17</elocation-id><history><date date-type="received"><day>16</day><month>11</month><year>2017</year></date><date date-type="rev-request"><day>20</day><month>1</month><year>2018</year></date><date date-type="accepted"><day>13</day><month>2</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2018 Guo et al.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Guo et al.</copyright-holder><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="zac005187122001.pdf"/><abstract><title>ABSTRACT</title><p><named-content content-type="genus-species">Mycobacterium abscessus</named-content> accounts for a large proportion of lung disease cases caused by rapidly growing mycobacteria. The association between clarithromycin sensitivity and treatment outcome is clear. However, <named-content content-type="genus-species">M. abscessus</named-content> culture and antibiotic susceptibility testing are time-consuming. Clarithromycin susceptibility genotyping offers an alternate, rapid approach to predicting the efficacy of clarithromycin-based antibiotic therapy. <named-content content-type="genus-species">M. abscessus</named-content> lung disease patients were divided into two groups based upon the clarithromycin susceptibility genotype of the organism isolated. A retrospective analysis was conducted to compare the clinical features, microbiological characteristics, and treatment outcomes of the two groups. Several other potential predictors of the response to treatment were also assessed. Sixty-nine patients were enrolled in the clarithromycin-resistant genotype group, which included 5 infected with <italic>rrl</italic> 2058-2059 mutants and 64 infected with <italic>erm</italic>(41)T28-type <named-content content-type="genus-species">M. abscessus</named-content>; 31 were in the clarithromycin-sensitive group, i.e., 6 and 25 patients infected with genotypes <italic>erm</italic>(41)C28 and <italic>erm</italic>(41) M type, respectively. The results showed that lung disease patients infected with clarithromycin-sensitive and -resistant <named-content content-type="genus-species">M. abscessus</named-content> genotypes differed significantly in clarithromycin-based combination treatment outcomes. Patients infected with the clarithromycin-sensitive genotype exhibited higher initial and final sputum-negative conversion and radiological improvement rates and better therapeutic outcomes. Multivariate analysis demonstrated that genotyping was a reliable and, more importantly, rapid means of predicting the efficacy of clarithromycin-based antibiotic treatment for <named-content content-type="genus-species">M. abscessus</named-content> lung disease.</p></abstract><kwd-group><title>KEYWORDS</title><kwd><named-content content-type="genus-species">Mycobacterium abscessus</named-content></kwd><kwd>clarithromycin</kwd><kwd>genotype</kwd><kwd>lung disease</kwd><kwd>treatment outcome</kwd></kwd-group><funding-group><award-group id="award1"><funding-source id="gs1"><institution-wrap><institution>Medical Guide Program of Shanghai Science and Technology Committee</institution></institution-wrap></funding-source><award-id rid="gs1">14411962900</award-id><principal-award-recipient><name><surname>Chu</surname><given-names>Haiqing</given-names></name></principal-award-recipient></award-group><award-group id="award2"><funding-source id="gs2"><institution-wrap><institution>Key Project of Shanghai Municipal Health and Family Planning Commission</institution></institution-wrap></funding-source><award-id rid="gs2">201540367</award-id><principal-award-recipient><name><surname>Chu</surname><given-names>Haiqing</given-names></name></principal-award-recipient></award-group><award-group id="award3"><funding-source id="gs3"><institution-wrap><institution>Youth Project of Shanghai Municipal Health and Family Planning Commission</institution></institution-wrap></funding-source><award-id rid="gs3">20164Y0230</award-id><principal-award-recipient><name><surname>Li</surname><given-names>Bing</given-names></name></principal-award-recipient></award-group><award-group id="award4"><funding-source id="gs4"><institution-wrap><institution>New Frontier Technology Joint Project of Municipal Hospital, Shanghai Shenkang Hospital Develoment Center</institution></institution-wrap></funding-source><award-id rid="gs4">SHDC12017113</award-id><principal-award-recipient><name><surname>Chu</surname><given-names>Haiqing</given-names></name></principal-award-recipient></award-group><award-group id="award5"><funding-source id="gs5"><institution-wrap><institution>National Natural Science Foundation of China (NSFC)</institution><institution-id>https://doi.org/10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id rid="gs5">81672063</award-id><principal-award-recipient><name><surname>Chu</surname><given-names>Haiqing</given-names></name></principal-award-recipient></award-group></funding-group><counts><count count="1" count-type="supplementary-material"/><fig-count count="2"/><table-count count="5"/><equation-count count="0"/><ref-count count="31"/><page-count count="11"/><word-count count="6732"/></counts><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1"><title>INTRODUCTION</title><p>The incidence of infections by nontuberculosis mycobacteria (NTM) has increased significantly in recent years (<xref rid="B1" ref-type="bibr">1</xref><xref ref-type="bibr" rid="B2">&#x02013;</xref><xref rid="B3" ref-type="bibr">3</xref>). Of all NTM infections, treatment of <named-content content-type="genus-species">Mycobacterium abscessus</named-content> infections is the most challenging (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>). <named-content content-type="genus-species">M. abscessus</named-content> accounts for 65 to 80% of the cases of lung disease caused by rapidly growing mycobacteria and has emerged as an important pathogen for patients with bronchiectasis, chronic obstructive pulmonary disease, and cystic fibrosis (<xref rid="B6" ref-type="bibr">6</xref><xref ref-type="bibr" rid="B7">&#x02013;</xref><xref rid="B11" ref-type="bibr">11</xref>).</p><p><named-content content-type="genus-species">M. abscessus</named-content> is among the most antibiotic-resistant pathogens known (<xref rid="B12" ref-type="bibr">12</xref>). Although some antibiotics, such as amikacin, cefoxitin, and imipenem, are effective, only clarithromycin (CLA) exhibits convincing evidence of clinical efficacy for treatment of <named-content content-type="genus-species">M. abscessus</named-content> lung disease (<xref rid="B8" ref-type="bibr">8</xref>). Currently, CLA is the only effective antibiotic administered orally and, therefore, recommended as the core agent for treatment of <named-content content-type="genus-species">M. abscessus</named-content> infections (<xref rid="B8" ref-type="bibr">8</xref>).</p><p>Genotypic variations influence the sensitivity of <named-content content-type="genus-species">M. abscessus</named-content> to CLA. Two genotypes confer CLA resistance: a point mutation (A to C or A to G) in the 2058-2059 locus of the 23S rRNA (<italic>rrl</italic>) gene confers acquired resistance (<xref rid="B13" ref-type="bibr">13</xref>). An intact <italic>erm</italic>(41) gene, which exhibits a T/C polymorphism at the 28th nucleotide, confers inducible resistance when the 28th nucleotide is thymidine [<italic>erm</italic>(41)T28] (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>). Alternatively, CLA sensitivity is conferred when cytidine is the 28th nucleotide in intact <italic>erm</italic>(41), i.e., genotype <italic>erm</italic>(41)C28 (<xref rid="B15" ref-type="bibr">15</xref>). Deletion of <italic>erm</italic>(41) nucleotides 64 and 65, or deletion of nucleotides 159 to 432, also results in the loss of <italic>erm</italic>(41) gene function (M type) and a gain in CLA sensitivity (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B16" ref-type="bibr">16</xref>).</p><p><named-content content-type="genus-species">M. abscessus</named-content> can be divided into <named-content content-type="genus-species">M. abscessus</named-content> subsp. <named-content content-type="genus-species">abscessus</named-content> and <named-content content-type="genus-species">M. abscessus</named-content> subsp. <named-content content-type="genus-species">massiliense</named-content> based upon the integrity or absence of the <italic>erm</italic>(41) gene. Korean and Japanese researchers first reported that <named-content content-type="genus-species">M. abscessus</named-content> subsp. <named-content content-type="genus-species">abscessus</named-content> and <named-content content-type="genus-species">M. abscessus</named-content> subsp. <named-content content-type="genus-species">massiliense</named-content> exhibited disparate clinical and microbiological characteristics (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>). Retrospective analysis and a prospective study conducted in 2017 confirmed these results and suggested that patients infected with a CLA-sensitive [<italic>erm</italic>(41)C28] genotype had a prognostic advantage (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>). Therefore, differences in the A and M subtypes may be due largely to genotypic differences that affect CLA sensitivity (<xref rid="B21" ref-type="bibr">21</xref><xref ref-type="bibr" rid="B22">&#x02013;</xref><xref rid="B23" ref-type="bibr">23</xref>). Here, we report the results of a retrospective analysis undertaken to determine the relationship between genotype, CLA sensitivity, and the outcome of CLA-based treatment of <named-content content-type="genus-species">M. abscessus</named-content> lung disease.</p></sec><sec sec-type="results" id="sec2"><title>RESULTS</title><sec id="sec2-1"><title>Patient characteristics.</title><p>One hundred <named-content content-type="genus-species">M. abscessus</named-content> lung disease patients who conformed to our recruitment criteria were enrolled and divided into CLA-resistant and -sensitive genotype groups according to the <italic>rrl</italic> and <italic>erm</italic>(41) sequevar. Sixty-nine (69%) patients were enrolled in the CLA-resistant genotype group, which included 5 (7.2%) <italic>rrl</italic> 2058-2059 mutant- and 64 (92.8%) <italic>erm</italic>(41)T28-type-infected patients; 31 (31%) belonged to the CLA-sensitive genotype group, which included 6 (19.4%) <italic>erm</italic>(41)C28- and 25 (80.6%) <italic>erm</italic>(41) M-type-infected patients. No significant differences were found in the ages and genders of the two groups (<xref ref-type="table" rid="T1">Table 1</xref>). The proportion of patients with hemoptysis was higher in the CLA-resistant genotype group than the CLA-sensitive genotype group (22/69 versus 4/31; <italic>P</italic> = 0.045). Furthermore, a significantly greater incidence of cavity-like manifestations occurred in computed tomography (CT) scans of patients infected with isolates with the CLA-resistant genotype than in patients infected with isolates with the CLA-sensitive genotype (50/69 versus 8/31; <italic>P</italic> &#x0003c; 0.001). CT scans of the CLA-sensitive-group patients, on the other hand, displayed a higher incidence of a tree-in-bud pattern (14/31 versus 16/69; <italic>P</italic> = 0.027).</p><table-wrap id="T1" orientation="portrait" position="float"><label>TABLE 1</label><caption><p>Baseline characteristics of patients infected with <named-content content-type="genus-species">M. abscessus</named-content> belonging to CLA-resistant and -sensitive genotypes</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr valign="bottom"><th rowspan="2" align="left" colspan="1">Characteristic<xref ref-type="table-fn" rid="T1F1"><sup><italic>a</italic></sup></xref></th><th colspan="2" align="left" rowspan="1">Value<xref ref-type="table-fn" rid="T1F2"><sup><italic>b</italic></sup></xref><hr/></th><th rowspan="2" align="left" colspan="1"><italic>P</italic> value</th></tr><tr valign="bottom"><th align="left" rowspan="1" colspan="1">CLA-resistant group (<italic>n</italic> = 69)</th><th align="left" rowspan="1" colspan="1">CLA-sensitive group (<italic>n</italic> = 31)</th></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1">Median age (IQR) (yr)</td><td rowspan="1" colspan="1">58 (44&#x02013;66)</td><td rowspan="1" colspan="1">56 (32&#x02013;64)</td><td rowspan="1" colspan="1">0.562</td></tr><tr valign="top"><td rowspan="1" colspan="1">Males</td><td rowspan="1" colspan="1">26 (37.7)</td><td rowspan="1" colspan="1">17 (54.8)</td><td rowspan="1" colspan="1">0.107</td></tr><tr valign="top"><td rowspan="1" colspan="1">BMI (mean &#x000b1; SD) (kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1">19.93 &#x000b1; 0.37</td><td rowspan="1" colspan="1">19.69 &#x000b1; 0.57</td><td rowspan="1" colspan="1">0.729</td></tr><tr valign="top"><td rowspan="1" colspan="1">Underlying disease</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Prior tuberculosis<xref ref-type="table-fn" rid="T1F3"><sup><italic>c</italic></sup></xref></td><td rowspan="1" colspan="1">29 (42.0)</td><td rowspan="1" colspan="1">16 (51.6)</td><td rowspan="1" colspan="1">0.373</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;COPD</td><td rowspan="1" colspan="1">1 (1.4)</td><td rowspan="1" colspan="1">2 (6.5)</td><td rowspan="1" colspan="1">0.226</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Hypertension</td><td rowspan="1" colspan="1">11 (15.9)</td><td rowspan="1" colspan="1">3 (9.7)</td><td rowspan="1" colspan="1">0.601</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Diabetes</td><td rowspan="1" colspan="1">2 (2.9)</td><td rowspan="1" colspan="1">4 (12.9)</td><td rowspan="1" colspan="1">0.135</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;CHD</td><td rowspan="1" colspan="1">4 (5.8)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">0.414</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Malignancy</td><td rowspan="1" colspan="1">3 (4.3)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">0.550</td></tr><tr valign="top"><td rowspan="1" colspan="1">History of surgery</td><td rowspan="1" colspan="1">3 (4.3)</td><td rowspan="1" colspan="1">1 (3.2)</td><td rowspan="1" colspan="1">1</td></tr><tr valign="top"><td rowspan="1" colspan="1">Symptoms</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Cough</td><td rowspan="1" colspan="1">55 (79.7)</td><td rowspan="1" colspan="1">25 (80.6)</td><td rowspan="1" colspan="1">0.914</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Sputum</td><td rowspan="1" colspan="1">69 (100.0)</td><td rowspan="1" colspan="1">31 (100.0)</td><td rowspan="1" colspan="1">1</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Fever</td><td rowspan="1" colspan="1">15 (21.7)</td><td rowspan="1" colspan="1">4 (12.9)</td><td rowspan="1" colspan="1">0.298</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Hemoptysis</td><td rowspan="1" colspan="1">22 (31.9)</td><td rowspan="1" colspan="1">4 (12.9)</td><td rowspan="1" colspan="1">0.045</td></tr><tr valign="top"><td rowspan="1" colspan="1">Radiographic features</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Extent</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.404</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;Bilateral involvement</td><td rowspan="1" colspan="1">58 (84.0)</td><td rowspan="1" colspan="1">28 (90.3)</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;Unilateral involvement</td><td rowspan="1" colspan="1">11 (15.9)</td><td rowspan="1" colspan="1">3 (9.7)</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Median no. of lobes (IQR)</td><td rowspan="1" colspan="1">4 (3&#x02013;6)</td><td rowspan="1" colspan="1">4 (2&#x02013;6)</td><td rowspan="1" colspan="1">0.419</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Disease pattern</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;Bronchiectasis</td><td rowspan="1" colspan="1">66 (95.7)</td><td rowspan="1" colspan="1">29 (93.4)</td><td rowspan="1" colspan="1">0.655</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;Cavity</td><td rowspan="1" colspan="1">50 (72.5)</td><td rowspan="1" colspan="1">8 (25.8)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;Nodules (diam &#x0003c; 1 cm)</td><td rowspan="1" colspan="1">38 (55.0)</td><td rowspan="1" colspan="1">19 (61.3)</td><td rowspan="1" colspan="1">0.561</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;Nodules (diam &#x0003e; 1 cm)</td><td rowspan="1" colspan="1">39 (56.5)</td><td rowspan="1" colspan="1">16 (51.6)</td><td rowspan="1" colspan="1">0.648</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;Tree-in-bud pattern</td><td rowspan="1" colspan="1">16 (23.2)</td><td rowspan="1" colspan="1">14 (45.2)</td><td rowspan="1" colspan="1">0.027</td></tr><tr valign="top"><td rowspan="1" colspan="1">Initial AFB smear positivity</td><td rowspan="1" colspan="1">28 (40.6)</td><td rowspan="1" colspan="1">10 (32.3)</td><td rowspan="1" colspan="1">0.428</td></tr><tr valign="top"><td rowspan="1" colspan="1">Initial morphotype</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.770</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Rough</td><td rowspan="1" colspan="1">40 (58.0)</td><td rowspan="1" colspan="1">17 (54.8)</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Smooth</td><td rowspan="1" colspan="1">29 (42.0)</td><td rowspan="1" colspan="1">14 (45.2)</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn fn-type="abbr" id="T1F1"><label>a</label><p>COPD, chronic obstructive pulmonary disease; CHD, coronary heart disease; AFB, acid-fast bacilli; IQR, interquartile range.</p></fn><fn fn-type="other" id="T1F2"><label>b</label><p>Data are the numbers (%) of patients found in the CLA-resistant and -sensitive genotype groups unless otherwise indicated.</p></fn><fn fn-type="other" id="T1F3"><label>c</label><p>Patients treated for tuberculosis prior to the diagnosis of <named-content content-type="genus-species">M. abscessus</named-content> lung disease.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2-2"><title>Colony morphology.</title><p><named-content content-type="genus-species">M. abscessus</named-content> isolates manifest two distinct colony morphotypes: smooth and rough. The colony morphology of the isolates associated with both CLA susceptibility groups did not differ significantly (<xref ref-type="table" rid="T1">Table 1</xref>). Patients infected with <named-content content-type="genus-species">M. abscessus</named-content> characterized by a rough-type colony exhibited a higher incidence of cavities in CT images (<italic>P</italic> = 0.043) (<xref ref-type="table" rid="T2">Table 2</xref>). The colony morphotype did not exert a significant effect on any of the other parameters assessed.</p><table-wrap id="T2" orientation="portrait" position="float"><label>TABLE 2</label><caption><p>Relationship between morphotype, results of initial CT scan, and treatment outcome</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr valign="bottom"><th rowspan="2" align="left" colspan="1">Parameter</th><th colspan="2" align="left" rowspan="1">No. (%) of patients<xref ref-type="table-fn" rid="T2F1"><sup><italic>a</italic></sup></xref><hr/></th><th rowspan="2" align="left" colspan="1"><italic>P</italic> value</th></tr><tr valign="bottom"><th align="left" rowspan="1" colspan="1">Rough <italic>n</italic> = 57</th><th align="left" rowspan="1" colspan="1">Smooth <italic>n</italic> = 43</th></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1">Radiographic features</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Bronchiectasis</td><td rowspan="1" colspan="1">56 (98.2)</td><td rowspan="1" colspan="1">39 (90.7)</td><td rowspan="1" colspan="1">0.211</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Tree-in-bud pattern</td><td rowspan="1" colspan="1">18 (31.6)</td><td rowspan="1" colspan="1">12 (27.9)</td><td rowspan="1" colspan="1">0.692</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Cavity</td><td rowspan="1" colspan="1">38 (66.7)</td><td rowspan="1" colspan="1">20 (46.5)</td><td rowspan="1" colspan="1">0.043</td></tr><tr valign="top"><td rowspan="1" colspan="1">Radiological improvement</td><td rowspan="1" colspan="1">26 (45.6)</td><td rowspan="1" colspan="1">21 (48.8)</td><td rowspan="1" colspan="1">0.749</td></tr><tr valign="top"><td rowspan="1" colspan="1">Sputum conversion to negativity</td><td rowspan="1" colspan="1">21 (36.8)</td><td rowspan="1" colspan="1">19 (44.2)</td><td rowspan="1" colspan="1">0.458</td></tr><tr valign="top"><td rowspan="1" colspan="1">Treatment effectiveness</td><td rowspan="1" colspan="1">31 (54.4)</td><td rowspan="1" colspan="1">25 (58.1)</td><td rowspan="1" colspan="1">0.708</td></tr></tbody></table><table-wrap-foot><fn fn-type="other" id="T2F1"><label>a</label><p>Number (percentage) of patients infected with isolates that give rise to rough and smooth colony types versus the disease parameter listed.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2-3"><title>Comparison of antibiotic sensitivity.</title><p>The sensitivity of all the <named-content content-type="genus-species">M. abscessus</named-content> isolates to 10 antibiotics tested is shown in <xref ref-type="table" rid="T3">Table 3</xref> and Table S1 in the supplemental material. The five <italic>rrl</italic> 2058-2059 mutant isolates exhibited acquired resistance to CLA, i.e., they were resistant on day 3 of exposure and prior to induction. Twenty-seven of the 64 <italic>erm</italic>(41)T28 isolates also exhibited acquired resistance; 36 isolates were induced by 14 days exposure to CLA; and one isolate showed abnormal CLA sensitivity despite expressing an <italic>erm</italic>(41)T28 gene, albeit with a wild-type <italic>rrl</italic> gene. In sharp contrast, no CLA resistance was observed within the CLA-sensitive genotype group. Notably, although most isolates in the CLA-resistant genotype group were insensitive to CLA, only one isolate was insensitive to amikacin treatment. A considerable number of isolates in both the CLA-sensitive and CLA-resistant genotype groups were sensitive to linezolid. A large number of isolates in both groups were resistant to moxifloxacin, doxycycline, imipenem, and tobramycin; no significant difference in resistance to these antibiotics was found between groups.</p><table-wrap id="T3" orientation="portrait" position="float"><label>TABLE 3</label><caption><p>Antibiotic resistance of all <named-content content-type="genus-species">M. abscessus</named-content> isolates<xref ref-type="table-fn" rid="T3F1"><sup><italic>a</italic></sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr valign="bottom"><th rowspan="2" align="left" colspan="1">Isolate group (<italic>n</italic>)</th><th rowspan="2" align="left" colspan="1">Antibiotic</th><th colspan="12" align="left" rowspan="1">No. of isolates/MIC (mg/ml) of:<hr/></th><th rowspan="2" align="left" colspan="1">No. (%) resistant isolates<xref ref-type="table-fn" rid="T3F2"><sup><italic>b</italic></sup></xref></th></tr><tr valign="bottom"><th align="left" rowspan="1" colspan="1">0.06</th><th align="left" rowspan="1" colspan="1">0.125</th><th align="left" rowspan="1" colspan="1">0.25</th><th align="left" rowspan="1" colspan="1">0.5</th><th align="left" rowspan="1" colspan="1">1</th><th align="left" rowspan="1" colspan="1">2</th><th align="left" rowspan="1" colspan="1">4</th><th align="left" rowspan="1" colspan="1">8</th><th align="left" rowspan="1" colspan="1">16</th><th align="left" rowspan="1" colspan="1">32</th><th align="left" rowspan="1" colspan="1">64</th><th align="left" rowspan="1" colspan="1">128</th></tr></thead><tbody><tr valign="top"><td rowspan="11" colspan="1">Resistant (69)</td><td rowspan="1" colspan="1">Clarithromycin before induction</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">28 (40.6)</td></tr><tr valign="top"><td rowspan="1" colspan="1">Clarithromycin after induction</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">68</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">68 (98.6)</td></tr><tr valign="top"><td rowspan="1" colspan="1">Amikacin</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1 (1.4)</td></tr><tr valign="top"><td rowspan="1" colspan="1">Linezolid</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">33</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">33 (47.8)</td></tr><tr valign="top"><td rowspan="1" colspan="1">Moxifloxacin</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">65</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">68 (98.6)</td></tr><tr valign="top"><td rowspan="1" colspan="1">Doxycycline</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">68</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">68 (98.6)</td></tr><tr valign="top"><td rowspan="1" colspan="1">Imipenem</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">66 (95.7)</td></tr><tr valign="top"><td rowspan="1" colspan="1">Tobramycin</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">60 (87.0)</td></tr><tr valign="top"><td rowspan="1" colspan="1">Cefoxitin</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">43</td><td rowspan="1" colspan="1">43 (62.3)</td></tr><tr valign="top"><td rowspan="1" colspan="1">Sulfonamides</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">38 (55.1)</td></tr><tr valign="top"><td rowspan="1" colspan="1">Tigecycline</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">ND</td></tr><tr valign="top"><td rowspan="11" colspan="1">Sensitive (31)</td><td rowspan="1" colspan="1">Clarithromycin before induction</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">6 (19.4)</td></tr><tr valign="top"><td rowspan="1" colspan="1">Clarithromycin after induction</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">8 (25.8)</td></tr><tr valign="top"><td rowspan="1" colspan="1">Amikacin</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1 (3.2)</td></tr><tr valign="top"><td rowspan="1" colspan="1">Linezolid</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">13 (42.0)</td></tr><tr valign="top"><td rowspan="1" colspan="1">Moxifloxacin</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">28</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">30 (96.8)</td></tr><tr valign="top"><td rowspan="1" colspan="1">Doxycycline</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">31 (100)</td></tr><tr valign="top"><td rowspan="1" colspan="1">Imipenem</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">30 (96.8)</td></tr><tr valign="top"><td rowspan="1" colspan="1">Tobramycin</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">30 (96.8)</td></tr><tr valign="top"><td rowspan="1" colspan="1">Cefoxitin</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">22 (71.0)</td></tr><tr valign="top"><td rowspan="1" colspan="1">Sulfonamides</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">18 (58.1)</td></tr><tr valign="top"><td rowspan="1" colspan="1">Tigecycline</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">ND</td></tr></tbody></table><table-wrap-foot><fn fn-type="other" id="T3F1"><label>a</label><p>The <italic>erm</italic>(41) sequevar-dependent resistance of 100 <named-content content-type="genus-species">M. abscessus</named-content> isolates to the antibiotics indicated was determined by the microdilution method. The incubation time was 3 days (before) and 14 days (after) induction for CLA and 3 days for the other antibiotics listed.</p></fn><fn fn-type="other" id="T3F2"><label>b</label><p>Resistant isolates were distinguished according to the breakpoint provided by NCCLS document M24-A2. ND, no data. Tigecycline has no recommended breakpoint.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2-4"><title>Combination antibiotic treatment and treatment response.</title><p>All patients enrolled in the study were treated with a standard combination of antibiotics based upon CLA. Patients infected with the CLA-sensitive genotype group isolates were significantly more likely to demonstrate initial sputum conversion (<xref ref-type="fig" rid="F1">Fig. 1</xref> and <xref ref-type="table" rid="T4">Table 4</xref>) (<italic>P</italic> = 0.011). Times to initial sputum conversion also differed significantly between the CLA-sensitive and CLA-resistant genotype groups (<italic>P</italic> = 004). Sputum relapse after initial conversion to negative occurred in both groups and did not differ significantly. The proportion of patients whose sputa converted and remained culture-negative during the follow-up period was significantly greater in the CLA-sensitive than in the CLA-resistant genotype group (61.3% versus 30.4%, respectively; <italic>P</italic> = 0.013). Radiographic improvement rates were significantly higher in patients infected with the CLA-sensitive genotype group isolates than in patients infected with the CLA-resistant genotype group (<italic>P</italic> = 0.006). The effective treatment response evaluated by radiology and microbiology was also significantly greater for the CLA-sensitive genotype group than for the CLA-resistant genotype group (<italic>P</italic> &#x0003c; 0.001).</p><fig id="F1" orientation="portrait" position="float"><label>FIG 1</label><caption><p>Comparison of initial sputum smear/culture conversion between patients infected with the CLA-resistant [2058-2059 <italic>rrl</italic> mutant or <italic>rrl</italic> wild type/<italic>erm</italic>(41)T28] and -sensitive [<italic>rrl</italic> wild type/<italic>erm</italic>(41)C28 or <italic>rrl</italic> wild type/<italic>erm</italic>(41) M type] genotype groups. Patients infected with the resistant group isolates showed a significantly longer initial sputum medium conversion time: 12 months versus 7 months for the sensitive group (<italic>P</italic> = 0.004).</p></caption><graphic xlink:href="zac0051871220001"/></fig><table-wrap id="T4" orientation="portrait" position="float"><label>TABLE 4</label><caption><p>Treatment outcomes for CLA-resistant and -sensitive genotype groups</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr valign="bottom"><th rowspan="2" align="left" colspan="1">Parameter</th><th colspan="2" align="left" rowspan="1">Value<xref ref-type="table-fn" rid="T4F1"><sup><italic>a</italic></sup></xref><hr/></th><th rowspan="2" align="left" colspan="1"><italic>P</italic> value</th></tr><tr valign="bottom"><th align="left" rowspan="1" colspan="1">Resistant group (<italic>n</italic> = 69)</th><th align="left" rowspan="1" colspan="1">Sensitive group (<italic>n</italic> = 31)</th></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1">Median duration of treatment [mo (IQR)]</td><td rowspan="1" colspan="1">18 (9&#x02013;30)</td><td rowspan="1" colspan="1">15 (9&#x02013;22)</td><td rowspan="1" colspan="1">0.260</td></tr><tr valign="top"><td rowspan="1" colspan="1">Sputum result</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.013</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Conversion to stable negative</td><td rowspan="1" colspan="1">21 (30.4)</td><td rowspan="1" colspan="1">19 (61.3)</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Failure to convert</td><td rowspan="1" colspan="1">39 (56.5)</td><td rowspan="1" colspan="1">9 (29.0)</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Relapse after conversion to negative</td><td rowspan="1" colspan="1">9 (13.0)</td><td rowspan="1" colspan="1">3 (9.7)</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Initial smear/culture conversion</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;No. of patients who initially converted</td><td rowspan="1" colspan="1">30 (43.5)</td><td rowspan="1" colspan="1">22 (71.0)</td><td rowspan="1" colspan="1">0.011</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Median time to initial conversion [mo (IQR)]</td><td rowspan="1" colspan="1">12 (6&#x02013;23)</td><td rowspan="1" colspan="1">7 (5&#x02013;11)</td><td rowspan="1" colspan="1">0.004</td></tr><tr valign="top"><td rowspan="1" colspan="1">Radiological result</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Improved</td><td rowspan="1" colspan="1">25 (36.2)</td><td rowspan="1" colspan="1">22 (71.0)</td><td rowspan="1" colspan="1">0.006</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;No change</td><td rowspan="1" colspan="1">24 (34.8)</td><td rowspan="1" colspan="1">5 (16.1)</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Progressed</td><td rowspan="1" colspan="1">20 (30.0)</td><td rowspan="1" colspan="1">4 (12.9)</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Final treatment response</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Effective</td><td rowspan="1" colspan="1">30 (43.5)</td><td rowspan="1" colspan="1">26 (83.9)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Failure</td><td rowspan="1" colspan="1">39 (56.5)</td><td rowspan="1" colspan="1">5 (16.1)</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn fn-type="other" id="T4F1"><label>a</label><p>The data are the number and (percentage) of patients in each group unless otherwise indicated.</p></fn></table-wrap-foot></table-wrap><p>In multivariate analysis, the genotype was a reliable predictor of the response of <named-content content-type="genus-species">M. abscessus</named-content> lung disease to treatment (odds ratio [OR] = 0.185; 95% confidence interval [CI], 0.059 to 0.579; <italic>P</italic> = 0.004) (<xref ref-type="table" rid="T5">Table 5</xref>). All other characteristics, i.e., age, sex, body mass index (BMI), colony morphology, and CT imaging, were nonpredictors.</p><table-wrap id="T5" orientation="portrait" position="float"><label>TABLE 5</label><caption><p>Univariate and multivariate analyses of factors affecting combination antibiotic treatment</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr valign="bottom"><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">Unadjusted OR (95% CI)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic> value</th><th align="left" rowspan="1" colspan="1">Adjusted OR (95% CI)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1">Age (yr)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x0003e;58</td><td rowspan="1" colspan="1">0.72 (0.33&#x02013;1.60)</td><td rowspan="1" colspan="1">0.421</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x0003c;58</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Male</td><td rowspan="1" colspan="1">1.93 (0.86&#x02013;4.36)</td><td rowspan="1" colspan="1">0.113</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Female</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">BMI</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x0003e;20.0</td><td rowspan="1" colspan="1">1.10 (0.48&#x02013;2.35)</td><td rowspan="1" colspan="1">0.884</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x0003c;20.0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Resistance of isolates</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Resistant</td><td rowspan="1" colspan="1">0.15 (0.051&#x02013;0.431)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">0.185 (0.059&#x02013;0.579)</td><td rowspan="1" colspan="1">0.004</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Sensitive</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Initial morphotype</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Rough</td><td rowspan="1" colspan="1">0.86 (0.39&#x02013;1.91)</td><td rowspan="1" colspan="1">0.708</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Smooth</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Positive AFB smear</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Yes</td><td rowspan="1" colspan="1">1.13 (0.50&#x02013;2.56)</td><td rowspan="1" colspan="1">0.765</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;No</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Bronchiectasis</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Yes</td><td rowspan="1" colspan="1">1.98 (0.32&#x02013;12.37)</td><td rowspan="1" colspan="1">0.467</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;No</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Tree-in-bud pattern</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Yes</td><td rowspan="1" colspan="1">2.91 (1.14&#x02013;7.42)</td><td rowspan="1" colspan="1">0.025</td><td rowspan="1" colspan="1">2.217 (0.810&#x02013;6.068)</td><td rowspan="1" colspan="1">0.121</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;No</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Cavity</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Yes</td><td rowspan="1" colspan="1">0.39 (0.17&#x02013;0.90)</td><td rowspan="1" colspan="1">0.027</td><td rowspan="1" colspan="1">0.776 (0.298&#x02013;2.022)</td><td rowspan="1" colspan="1">0.603</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;No</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Completed the initial 4 wk of treatment</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Yes</td><td rowspan="1" colspan="1">1.38 (0.55&#x02013;3.45)</td><td rowspan="1" colspan="1">0.498</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;No</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap></sec></sec><sec sec-type="discussion" id="sec3"><title>DISCUSSION</title><p>The study reported here was the first undertaken to explore and correlate the differences in treatment outcomes of <named-content content-type="genus-species">M. abscessus</named-content> lung disease patients with the CLA susceptibility genotype of clinical isolates. We found that the treatment results for patients infected with isolates with the CLA-sensitive <named-content content-type="genus-species">M. abscessus</named-content> genotype were far superior to the results for patients infected with isolates with the CLA-resistant genotype evaluated in terms of sputum conversion rate, duration of initial sputum conversion, radiological improvement, and efficacy. Treatment outcome, however, was independent of all other factors examined, which included BMI, colony morphology, and radiological images.</p><p>In 2006, the <named-content content-type="genus-species">M. abscessus</named-content> complex was first divided into <named-content content-type="genus-species">M. abscessus</named-content> subsp. <named-content content-type="genus-species">abscessus</named-content> and <named-content content-type="genus-species">M. abscessus</named-content> subsp. <named-content content-type="genus-species">massiliense</named-content> based upon differences in the <italic>rpoB</italic> gene (<xref rid="B24" ref-type="bibr">24</xref>). In 2011, Bastian and coworkers reported that variations in the <italic>erm</italic>(41) genotype influenced the sensitivity of these subtypes to CLA <italic>in vitro</italic> (<xref rid="B15" ref-type="bibr">15</xref>). The clinical characteristics and treatment outcomes of patients infected with <named-content content-type="genus-species">M. abscessus</named-content> subsp. <named-content content-type="genus-species">abscessus</named-content> and <named-content content-type="genus-species">M. abscessus</named-content> subsp. <named-content content-type="genus-species">massiliense</named-content> differed in subsequent studies (<xref rid="B17" ref-type="bibr">17</xref><xref ref-type="bibr" rid="B18">&#x02013;</xref><xref rid="B20" ref-type="bibr">20</xref>). Patients infected with <named-content content-type="genus-species">M. abscessus</named-content> subsp. <named-content content-type="genus-species">massiliense</named-content> usually responded better to treatment due, in part, to the CLA sensitivity of the organism. Several genotypes are associated with CLA sensitivity and -resistance: <italic>rrl</italic> mutant/wild type, <italic>erm</italic>(41)T28, <italic>erm</italic>(41)C28, and <italic>erm</italic>(41) M type. In the study described here, clinical isolates were grouped into these genotypes rather than <named-content content-type="genus-species">M. abscessus</named-content> subsp. <named-content content-type="genus-species">abscessus</named-content> and <named-content content-type="genus-species">M. abscessus</named-content> subsp. <named-content content-type="genus-species">massiliense</named-content>, and the responses of patients to standard, CLA-based treatment were assessed and compared. The response of the CLA-sensitive genotype group was significantly superior to that of the CLA-resistant genotype group judged in terms of the sputum conversion rate, radiological improvement, duration of initial sputum conversion results, and treatment efficacy. While lung disease patients infected with <named-content content-type="genus-species">M. abscessus</named-content> subsp<named-content content-type="genus-species">. abscessus</named-content> [<italic>erm</italic>(41)C28 genotype] isolates may exhibit a better response to combination CLA treatment, the response of patients infected with <named-content content-type="genus-species">M. abscessus</named-content> subsp. <named-content content-type="genus-species">massiliense</named-content> isolates expressing the 2058-2059 <italic>rrl</italic> mutation was often much worse. As such, CLA susceptibility genotyping is more accurate than subtyping as an approach to predicting the treatment outcomes of patients with <named-content content-type="genus-species">M. abscessus</named-content> lung disease (46.4% versus 42.9% true-positive rates, respectively).</p><p>The effect of BMI on the treatment outcomes of patients with NTM lung disease was demonstrated in several studies (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>). A recent retrospective study suggested that, in addition to CLA sensitivity, BMI was a factor that affected the success of <named-content content-type="genus-species">M. abscessus</named-content> lung disease treatment (<xref rid="B20" ref-type="bibr">20</xref>). This suggestion, however, was not confirmed by the present study. The overall BMIs of <named-content content-type="genus-species">M. abscessus</named-content> lung disease patients enrolled in our study were low; moreover, multivariate analysis failed to support its value in predicting an effective treatment outcome. This finding is consistent with results reported by other investigators (<xref rid="B19" ref-type="bibr">19</xref>). Similarly, predictions concerning the outcome of antibiotic therapy based upon symptoms or CT imaging are unrealistic. While hemoptysis and cavity-like manifestations were more common among the patients infected with CLA-resistant genotype <named-content content-type="genus-species">M. abscessus</named-content>, these factors failed to predict the prognosis upon multivariate analysis.</p><p>Patients infected with <named-content content-type="genus-species">M. abscessus</named-content> characterized by a rough-type colony exhibited a high incidence of cavities in CT images. This finding is consistent with the conclusion that rough-type strains usually exhibit higher virulence and pathogenicity. Unlike previous studies (<xref rid="B19" ref-type="bibr">19</xref>), however, we found that the initial colony morphology failed to correlate with the final radiologic improvement rate or treatment efficacy (<xref ref-type="table" rid="T2">Table 2</xref>). Jonsson and coworkers reported a significant increase in the number of rough colonies during the course of infection and the occurrence of smooth-to-rough colony conversion (<xref rid="B27" ref-type="bibr">27</xref>). Thus, we speculate that colony morphology is associated only with pathogenicity and the pathogenesis of infection and is not a reliable predictor of treatment efficacy.</p><p>The study described here has several limitations. First, only a relative small number of isolates exhibited the <italic>rrl</italic> mutation and <italic>erm</italic>(41)C28 genotypes; consequently, their characteristics may not be representative. Solidifying their characteristics will require the enrollment of more patients infected with isolates exhibiting the <italic>rrl</italic> mutant and <italic>erm</italic>(41)C28 genotypes in future studies. Second, a minority of patients relapsed following initially successful treatment (see Table S2 in the supplemental material). Conceivably, these relapses were due to subsequent infection by a different <named-content content-type="genus-species">M. abscessus</named-content> strain or genotype. In the absence of dynamic follow-up, our study failed to determine whether recurrence occurred due to reinfection by a different <named-content content-type="genus-species">M. abscessus</named-content> strain.</p><p>In conclusion, there was a significant difference in treatment outcomes for patients infected with CLA-resistant and -sensitive <named-content content-type="genus-species">M. abscessus</named-content> genotype isolates. The CLA-sensitive genotype group was significantly superior in sputum conversion rate, initial sputum conversion time, radiological improvement, and treatment efficacy. Accurate genotyping is an important factor in predicting the efficacy of combination therapy with CLA-based antibiotics. Rapid genotyping should help clinicians optimize therapeutic strategies, especially in cases of critically ill patients who cannot wait weeks for culture and susceptibility testing. Genotyping would also be effective as a diagnostic approach in areas where facilities for mycobacterial culture and susceptibility testing are unavailable.</p></sec><sec sec-type="materials|methods" id="sec4"><title>MATERIALS AND METHODS</title><sec id="sec4-1"><title>Study population.</title><p>A retrospective review of the medical records of all patients with <named-content content-type="genus-species">M. abscessus</named-content> lung disease was conducted between January 2012 and December 2015 at the Shanghai Pulmonary Hospital. Patient inclusion criteria were as follows: (i) age, &#x0003e;16 years; (ii) underwent initial diagnosis and treatment at the Shanghai Pulmonary Hospital in accordance with the 2007 American Thoracic Society/Infectious Disease Society of America (ATS/IDSA) guidelines; (iii) received oral CLA-based combination treatment; (iv) follow-up period lasted more than 6 months. The exclusion criteria were as follows: (i) age, &#x0003c;16 years; (ii) history of NTM lung disease; (iii) lack of critical visit data (e.g., regular sputum culture or CT examination), failure to follow up, or death from non-<named-content content-type="genus-species">M. abscessus</named-content> lung disease-related causes; (iv) treatment did not include oral CLA; (v) history of long-term macrolide drug treatment; (vi) diagnosed with active tuberculosis or received antituberculosis treatment within 3 months prior to study enrollment; (vii) coinfected with another nontuberculosis mycobacterium; (viii) refused to sign informed consent form; (ix) AIDS. In addition, patients with cystic fibrosis were not included in the study; notably, cystic fibrosis is extremely rare among Asian patients. A detailed, patient enrollment flow chart is shown in <xref ref-type="fig" rid="F2">Fig. 2</xref>. This study was approved by the Ethics Committees of Shanghai Pulmonary Hospital and Tongji University School of Medicine, ethics number K17-150. All participants signed informed consent forms before enrollment.</p><fig id="F2" orientation="portrait" position="float"><label>FIG 2</label><caption><p>Flow diagram of the study. One hundred <named-content content-type="genus-species">M. abscessus</named-content> lung disease patients who conformed to the inclusion criteria were enrolled. Sixty-nine patients were in the CLA-resistant genotype group, including 5 patients infected with <italic>rrl</italic> 2058-2059 mutants and 64 <italic>erm</italic>(41)T28-type-infected patients; 31 belonged to the CLA-sensitive group, including 6 <italic>erm</italic>(41)C28- and 25 <italic>erm</italic>(41) M-type-infected patients.</p></caption><graphic xlink:href="zac0051871220002"/></fig></sec><sec id="sec4-2"><title>Collection, identification, and preservation of bacteria.</title><p>All the clinical <named-content content-type="genus-species">M. abscessus</named-content> isolates used in this study were preserved in the Clinical Microbiology Laboratory of Shanghai Pulmonary Hospital. Shanghai Pulmonary Hospital is one of the designated treatment centers for tuberculosis and NTM disease in China, attracting NTM disease cases nationwide. <named-content content-type="genus-species">M. abscessus</named-content> isolates were obtained from sputum and bronchoalveolar lavage fluid. Samples were transferred to Lowenstein-Jensen (L-J) agar plates after treatment with 4% NaOH. Smears prepared from the bacterial colonies that grew were stained and examined microscopically to identify the acid-fast organisms. To select further NTM, positive colonies were inoculated and cultured in L-J medium containing 0.5 mg/ml P-nitrobenzoic acid and 5 mg/ml 2-thiophenecarboxylic acid hydrazide for 1 to 2 weeks at 37&#x000b0;C. Bacterial isolates that grew rapidly were selected for molecular typing by PCR. The bacteria were digested with 1 mg/ml lysozyme and 1 mg/ml proteinase K, and the DNA was extracted with phenol-chloroform. First, the <italic>rpoB</italic> gene was amplified by PCR, and the DNA sequences were determined. To confirm the <named-content content-type="genus-species">M. abscessus</named-content> complexes, 754 bp of the DNA segment was subjected to BLAST analysis. Second, the <italic>erm</italic>(41) gene was amplified, and the DNA sequence was analyzed to identify and differentiate <named-content content-type="genus-species">M. abscessus</named-content> subsp. <named-content content-type="genus-species">massiliense</named-content>, <named-content content-type="genus-species">M. abscessus</named-content> subsp. <named-content content-type="genus-species">abscessus</named-content>, and <named-content content-type="genus-species">M. abscessus</named-content> subsp. <named-content content-type="genus-species">bolletii</named-content>. Finally, the <italic>PRA-hsp65</italic> gene was compared to an online reference (<ext-link ext-link-type="uri" xlink:href="http://app.chuv.ch/prasite/index.html">http://app.chuv.ch/prasite/index.html</ext-link>) to confirm the <named-content content-type="genus-species">M. abscessus</named-content> subsp. <named-content content-type="genus-species">abscessus</named-content> and <named-content content-type="genus-species">M. abscessus</named-content> subsp. <named-content content-type="genus-species">bolletii</named-content> identifications. <named-content content-type="genus-species">M. abscessus</named-content> subsp. <italic>bolletii</italic> was excluded from the study because it is essentially absent in China. Identified <named-content content-type="genus-species">M. abscessus</named-content> subsp. <named-content content-type="genus-species">abscessus</named-content> and <named-content content-type="genus-species">M. abscessus</named-content> subsp. <named-content content-type="genus-species">massiliense</named-content> isolates, stored at &#x02212;80&#x000b0;C, were subsequently recovered for microbiology and molecular biology studies.</p></sec><sec id="sec4-3"><title>Identification of colony morphology.</title><p>Single colonies were obtained from frozen <named-content content-type="genus-species">M. abscessus</named-content> isolates by growth on Middlebrook 7H10 agar plates supplemented with 10% oleic acid-albumin-dextrose-catalase. The colonies were classified macroscopically as smooth or rough. If isolates gave rise to colonies of both morphotypes, a colony of each type was analyzed separately, and the identity was established by whole-genome sequencing.</p></sec><sec id="sec4-4"><title>Genotype analysis.</title><p>Genomic information for all isolates was obtained by whole-genome sequencing. Single nucleotide polymorphism (SNP) analysis was performed using the NCBI GenBank database and BLAST algorithm. The following genotypes were of specific interest: <italic>erm</italic>(41) [including <italic>erm</italic>(41)C28, <italic>erm</italic>(41)T28, and <italic>erm</italic>(41) M type], <italic>rll</italic> wild type, and <italic>rrl</italic> 2058-2059 mutant.</p></sec><sec id="sec4-5"><title>(i) Whole-genome sequencing.</title><p>Detailed methods were published previously by us (<xref rid="B28" ref-type="bibr">28</xref>). DNA was extracted according to the method of Somerville and coworkers (<xref rid="B29" ref-type="bibr">29</xref>), and paired-end libraries with insert sizes of &#x0223c;400 bp were prepared following Illumina's standard genomic DNA library preparation protocol (Illumina, San Diego, CA, USA). After shearing, ligating, and PCR, the qualified Illumina paired-end library was used for Illumina HiSeq sequencing (paired-end 150 bp &#x000d7; 2). The default parameters of the SPAdes software (version v.3.6.0) (<ext-link ext-link-type="uri" xlink:href="http://bioinf.spbau.ru/en/spades">http://bioinf.spbau.ru/en/spades</ext-link>) were used to assemble the genome draft (<xref rid="B30" ref-type="bibr">30</xref>). The assembled product was evaluated using QUAST (version v.2.3) (<xref rid="B31" ref-type="bibr">31</xref>; <ext-link ext-link-type="uri" xlink:href="http://quast.bioinf.spbau.ru/">http://quast.bioinf.spbau.ru/</ext-link>).</p></sec><sec id="sec4-6"><title>(ii) SNP analysis.</title><p>The NCBI Nucleotide BLAST program was used for SNP analysis. The standard ATCC 19977 (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/NC_010397.1" assigning-authority="genbank">NC_010397.1</ext-link>) <named-content content-type="genus-species">M. abscessus</named-content> strain served as the reference for <italic>rrl</italic> and <italic>erm</italic>(41)T28, CR5701 (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nucleotide/HQ127366.1" assigning-authority="genbank">HQ127366.1</ext-link>) was used as the reference strain for <italic>erm</italic>(41)C28, and CCUG48898 (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nucleotide/AP014547.1" assigning-authority="genbank">AP014547.1</ext-link>) was the reference for M type.</p></sec><sec id="sec4-7"><title>Drug sensitivity assay.</title><p>Antibiotic sensitivity was determined by the microdilution method. Sulfonamides, moxifloxacin, cefoxitin, amikacin, doxycycline, tigecycline, CLA, linezolid, imipenem, and tobramycin are among the most common antibiotics used to treat <named-content content-type="genus-species">M. abscessus</named-content> infections; each was tested (TREK Diagnostic Systems, Brooklyn Heights, OH, USA). CLA resistance was assessed at 3 days and 14 days after <named-content content-type="genus-species">M. abscessus</named-content> exposure. Antibiotics' susceptible and resistant breakpoints were interpreted according to Clinical and Laboratory Standards Institute (CLSI) document M24-A2. <named-content content-type="genus-species">Staphylococcus aureus</named-content> (ATCC 29213; American Type Culture Collection, Manassas, VA, USA) served as the control reference strain.</p></sec><sec id="sec4-8"><title>Treatment regimen and efficacy evaluation.</title><p>All patients were treated with antibiotics as follows: an initial 4-week course of amikacin (15 mg/kg of body weight/day in two equal doses) combined with cefoxitin (200 mg/kg/day with a maximum of 12 g/day in three equal doses) by intravenous administration. CLA was also administered orally from the beginning of therapy. After 4 weeks, an oral regimen of CLA combined with levofloxacin or moxifloxacin was given. If an adverse reaction to either amikacin or cefoxitin occurred, the regimen was replaced with imipenem (500 mg three times a day), linezolid (600 mg once every 12 h), or tigecycline (100 mg initially, followed by 50 mg every 12 h). CLA was administered continually throughout the course of treatment as recommended in the guidelines.</p><p>All the patients underwent chest CT examination, as well as sputum smears and culture, regularly. Therapeutic efficacy was determined according to the results of microbiological examination and radiological changes. The clinical characteristics, sputum culture conversion rate and time, radiological improvement rate, and microbiological characteristics of each genotype group were compared. Culture conversion was defined as three consecutive negative cultures from sputum specimens. Effective treatment was defined as sputum culture negative or significant pulmonary lesion resolution without recurrence during the observation period. Ineffective treatment included failure to achieve culture and smear conversion, recurrence after initial culture conversion, and appearance of increased or stable lesions in CT scans.</p></sec><sec id="sec4-9"><title>Statistical analysis.</title><p>All statistical analyses were conducted using SPSS20.0 (IBM, Armonk, NY, USA). The data were compared using Student's <italic>t</italic> test or the Mann-Whitney <italic>U</italic> test for continuous variables and the Pearson &#x003c7;<sup>2</sup> test or Fisher exact test for categorical variables. <italic>P</italic> values of &#x0003c;0.05 were considered statistically significant in a 2-tailed analysis. Times to initial culture conversion were compared using the Kaplan-Meier method. Potential predictors of the treatment response were assessed by multivariable logistic regression. In the logistic regression models, variables with <italic>P</italic> values of &#x0003c;0.1 in the univariable analysis were included in the multivariable analysis.</p></sec><sec id="sec4-10"><title>Accession number(s).</title><p>The accession numbers for all the <named-content content-type="genus-species">M. abscessus</named-content> isolates sequenced in this study are available at DDBJ/ENA/GenBank under BioProject <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA398137" assigning-authority="bioproject">PRJNA398137</ext-link>.</p></sec></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Supplemental material</title>
</caption>
<media mimetype="text" mime-subtype="html"
xlink:href="supp_62_5_e02360-17__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf"
xlink:href="AAC.02360-17_zac005187122s1.pdf"/>
</supplementary-material>
</sec>
</body><back><fn-group><fn fn-type="supplementary-material"><p>Supplemental material for this article may be found at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.02360-17">https://doi.org/10.1128/AAC.02360-17</ext-link>.</p></fn></fn-group><ack><title>ACKNOWLEDGMENTS</title><p>We declare no conflict of interest.</p><p>This project was supported by grants obtained from the National Natural Science Foundation of China (no. 81672063); the Medical Guide Program of Shanghai Science and Technology Committee (no. 14411962900); the Key Project of Shanghai Municipal Health and Family Planning Commission (no. 201540367); the Youth Project of Shanghai Municipal Health and Family Planning Commission (no. 20164Y0230); and the New Frontier Technology Joint Project of Municipal Hospital, Shanghai Shenkang Hospital Development Center (no. SHDC12017113).</p><p>We sincerely thank Stephen H. Gregory (Providence, Rhode Island, USA), who helped write and edit the manuscript.</p></ack><ref-list><title>REFERENCES</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prevots</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Marras</surname><given-names>TK</given-names></name></person-group>
<year>2015</year>
<article-title>Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review</article-title>. <source>Clin Chest Med</source>
<volume>36</volume>:<fpage>13</fpage>&#x02013;<lpage>34</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ccm.2014.10.002</pub-id>.<pub-id pub-id-type="pmid">25676516</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoefsloot</surname><given-names>W</given-names></name>, <name name-style="western"><surname>van Ingen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Andrejak</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Angeby</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Bauriaud</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Bemer</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Beylis</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Boeree</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Cacho</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chihota</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Chimara</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Churchyard</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Cias</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Daza</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Daley</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Dekhuijzen</surname><given-names>PN</given-names></name>, <name name-style="western"><surname>Domingo</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Drobniewski</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Esteban</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Fauville-Dufaux</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Folkvardsen</surname><given-names>DB</given-names></name>, <name name-style="western"><surname>Gibbons</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Gomez-Mampaso</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Gonzalez</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Hoffmann</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Hsueh</surname><given-names>PR</given-names></name>, <name name-style="western"><surname>Indra</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Jagielski</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Jamieson</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Jankovic</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Jong</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Keane</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Koh</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Lange</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Leao</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Macedo</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Mannsaker</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Marras</surname><given-names>TK</given-names></name>, <name name-style="western"><surname>Maugein</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Milburn</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Mlinko</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Morcillo</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Morimoto</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Papaventsis</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Palenque</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Paez-Pena</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Piersimoni</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Polanova</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rastogi</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Richter</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ruiz-Serrano</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Silva</surname><given-names>A</given-names></name>, <name name-style="western"><surname>da Silva</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Simsek</surname><given-names>H</given-names></name>, <name name-style="western"><surname>van Soolingen</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Szab&#x000f3;</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Thomson</surname><given-names>R</given-names></name>, <name name-style="western"><surname>T&#x000f3;rtola Fernandez</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Tortoli</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Totten</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Tyrrell</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Vasankari</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Villar</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Walkiewicz</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Winthrop</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Wagner</surname><given-names>D</given-names></name></person-group>, <collab>Nontuberculous Mycobacteria Network European Trials Group</collab>. <year>2013</year>
<article-title>The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study</article-title>. <source>Eur Respir J</source>
<volume>42</volume>:<fpage>1604</fpage>&#x02013;<lpage>1613</lpage>. doi:<pub-id pub-id-type="doi">10.1183/09031936.00149212</pub-id>.<pub-id pub-id-type="pmid">23598956</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brode</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Daley</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Marras</surname><given-names>TK</given-names></name></person-group>
<year>2014</year>
<article-title>The epidemiologic relationship between tuberculosis and non-tuberculous mycobacterial disease: a systematic review</article-title>. <source>Int J Tuberc Lung Dis</source>
<volume>18</volume>:<fpage>1370</fpage>&#x02013;<lpage>1377</lpage>. doi:<pub-id pub-id-type="doi">10.5588/ijtld.14.0120</pub-id>.<pub-id pub-id-type="pmid">25299873</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guimaraes</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Chimara</surname><given-names>E</given-names></name>, <name name-style="western"><surname>do Prado</surname><given-names>GV</given-names></name>, <name name-style="western"><surname>Ferrazoli</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Carvalho</surname><given-names>NG</given-names></name>, <name name-style="western"><surname>Simeao</surname><given-names>FC</given-names></name>, <name name-style="western"><surname>de Souza</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Costa</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Viana Niero</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Brianesi</surname><given-names>UA</given-names></name>, <name name-style="western"><surname>di Gioia</surname><given-names>TR</given-names></name>, <name name-style="western"><surname>Gomes</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Spadao</surname><given-names>FS</given-names></name>, <name name-style="western"><surname>Silva</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>de Moura</surname><given-names>EG</given-names></name>, <name name-style="western"><surname>Levin</surname><given-names>AS</given-names></name></person-group>
<year>2016</year>
<article-title>Pseudooutbreak of rapidly growing mycobacteria due to <italic>Mycobacterium abscessus</italic> subsp. <italic>bolletii</italic> in a digestive and respiratory endoscopy unit caused by the same clone as that of a countrywide outbreak</article-title>. <source>Am J Infect Control</source>
<volume>44</volume>:<elocation-id>e221&#x02013;e226</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.ajic.2016.06.019</pub-id>.<pub-id pub-id-type="pmid">27524260</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bryant</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Grogono</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Rodriguez-Rincon</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Everall</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>KP</given-names></name>, <name name-style="western"><surname>Moreno</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Verma</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Hill</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Drijkoningen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gilligan</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Esther</surname><given-names>CR</given-names></name>, <name name-style="western"><surname>Noone</surname><given-names>PG</given-names></name>, <name name-style="western"><surname>Giddings</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Bell</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Thomson</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Wainwright</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Coulter</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Pandey</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wood</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Stockwell</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Ramsay</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Sherrard</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Kidd</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Jabbour</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>GR</given-names></name>, <name name-style="western"><surname>Knibbs</surname><given-names>LD</given-names></name>, <name name-style="western"><surname>Morawska</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Sly</surname><given-names>PD</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bilton</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Laurenson</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Ruddy</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bourke</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bowler</surname><given-names>IC</given-names></name>, <name name-style="western"><surname>Chapman</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Clayton</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Cullen</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Dempsey</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Denton</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Desai</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Drew</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Edenborough</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Evans</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Folb</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Daniels</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Humphrey</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Isalska</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Jensen-Fangel</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jonsson</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Katzenstein</surname><given-names>TL</given-names></name>, <name name-style="western"><surname>Lillebaek</surname><given-names>T</given-names></name>, <name name-style="western"><surname>MacGregor</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Mayell</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Millar</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Modha</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Nash</surname><given-names>EF</given-names></name>, <name name-style="western"><surname>O'Brien</surname><given-names>C</given-names></name>, <name name-style="western"><surname>O'Brien</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Ohri</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Pao</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Peckham</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Perrin</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Perry</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Pressler</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Prtak</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Qvist</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Robb</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Rodgers</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Schaffer</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Shafi</surname><given-names>N</given-names></name>, <name name-style="western"><surname>van Ingen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Walshaw</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Watson</surname><given-names>D</given-names></name>, <name name-style="western"><surname>West</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Whitehouse</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Haworth</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Harris</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Ordway</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Parkhill</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Floto</surname><given-names>RA</given-names></name></person-group>
<year>2016</year>
<article-title>Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium</article-title>. <source>Science</source>
<volume>354</volume>:<fpage>751</fpage>&#x02013;<lpage>757</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.aaf8156</pub-id>.<pub-id pub-id-type="pmid">27846606</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Floto</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Olivier</surname><given-names>KN</given-names></name>, <name name-style="western"><surname>Saiman</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Daley</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Herrmann</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Nick</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Noone</surname><given-names>PG</given-names></name>, <name name-style="western"><surname>Bilton</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Corris</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Gibson</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Hempstead</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Koetz</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Sabadosa</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Sermet-Gaudelus</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Smyth</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>van Ingen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wallace</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Winthrop</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Marshall</surname><given-names>BC</given-names></name>, <name name-style="western"><surname>Haworth</surname><given-names>CS</given-names></name></person-group>
<year>2016</year>
<article-title>US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary</article-title>. <source>Thorax</source>
<volume>71</volume>:<fpage>88</fpage>&#x02013;<lpage>90</lpage>. doi:<pub-id pub-id-type="doi">10.1136/thoraxjnl-2015-207983</pub-id>.<pub-id pub-id-type="pmid">26678435</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Floto</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Olivier</surname><given-names>KN</given-names></name>, <name name-style="western"><surname>Saiman</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Daley</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Herrmann</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Nick</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Noone</surname><given-names>PG</given-names></name>, <name name-style="western"><surname>Bilton</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Corris</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Gibson</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Hempstead</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Koetz</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Sabadosa</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Sermet-Gaudelus</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Smyth</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>van Ingen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wallace</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Winthrop</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Marshall</surname><given-names>BC</given-names></name>, <name name-style="western"><surname>Haworth</surname><given-names>CS</given-names></name></person-group>, <collab>US Cystic Fibrosis Foundation, European Cystic Fibrosis Society</collab>. <year>2016</year>
<article-title>US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis</article-title>. <source>Thorax</source>
<volume>71</volume>(<issue>Suppl 1</issue>):<fpage>i1</fpage>&#x02013;<lpage>22</lpage>. doi:<pub-id pub-id-type="doi">10.1136/thoraxjnl-2015-207360</pub-id>.<pub-id pub-id-type="pmid">26666259</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Griffith</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Aksamit</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Brown-Elliott</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Catanzaro</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Daley</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Gordin</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Holland</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Horsburgh</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Huitt</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Iademarco</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Iseman</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Olivier</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ruoss</surname><given-names>S</given-names></name>, <name name-style="western"><surname>von Reyn</surname><given-names>CF</given-names></name>, <name name-style="western"><surname>Wallace</surname><given-names>RJ</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Winthrop</surname><given-names>K</given-names></name></person-group>, <collab>ATS Mycobacterial Diseases Subcommittee, American Thoracic Society, Infectious Disease Society of America</collab>. <year>2007</year>
<article-title>An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases</article-title>. <source>Am J Respir Crit Care Med</source>
<volume>175</volume>:<fpage>367</fpage>&#x02013;<lpage>416</lpage>. doi:<pub-id pub-id-type="doi">10.1164/rccm.200604-571ST</pub-id>.<pub-id pub-id-type="pmid">17277290</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Griffith</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Girard</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Wallace</surname><given-names>RJ</given-names><suffix>Jr</suffix></name></person-group>
<year>1993</year>
<article-title>Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients</article-title>. <source>Am Rev Respir Dis</source>
<volume>147</volume>:<fpage>1271</fpage>&#x02013;<lpage>1278</lpage>. doi:<pub-id pub-id-type="doi">10.1164/ajrccm/147.5.1271</pub-id>.<pub-id pub-id-type="pmid">8484642</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>CK</given-names></name>, <name name-style="western"><surname>Chou</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Hsu</surname><given-names>HL</given-names></name>, <name name-style="western"><surname>Liao</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>YT</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>PC</given-names></name>, <name name-style="western"><surname>Luh</surname><given-names>KT</given-names></name>, <name name-style="western"><surname>Hsueh</surname><given-names>PR</given-names></name></person-group>
<year>2010</year>
<article-title>Increasing incidence of nontuberculous mycobacteria, Taiwan, 2000-2008</article-title>. <source>Emerg Infect Dis</source>
<volume>16</volume>:<fpage>294</fpage>&#x02013;<lpage>296</lpage>. doi:<pub-id pub-id-type="doi">10.3201/eid1602.090675</pub-id>.<pub-id pub-id-type="pmid">20113563</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marras</surname><given-names>TK</given-names></name>, <name name-style="western"><surname>Mendelson</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Marchand-Austin</surname><given-names>A</given-names></name>, <name name-style="western"><surname>May</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Jamieson</surname><given-names>FB</given-names></name></person-group>
<year>2013</year>
<article-title>Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010</article-title>. <source>Emerg Infect Dis</source>
<volume>19</volume>:<fpage>1889</fpage>&#x02013;<lpage>1891</lpage>. doi:<pub-id pub-id-type="doi">10.3201/eid1911.130737</pub-id>.<pub-id pub-id-type="pmid">24210012</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nessar</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Cambau</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Reyrat</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Murray</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gicquel</surname><given-names>B</given-names></name></person-group>
<year>2012</year>
<article-title><italic>Mycobacterium abscessus</italic>: a new antibiotic nightmare</article-title>. <source>J Antimicrob Chemother</source>
<volume>67</volume>:<fpage>810</fpage>&#x02013;<lpage>818</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jac/dkr578</pub-id>.<pub-id pub-id-type="pmid">22290346</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallace</surname><given-names>RJ</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Meier</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Sander</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Onyi</surname><given-names>GO</given-names></name>, <name name-style="western"><surname>Bottger</surname><given-names>EC</given-names></name></person-group>
<year>1996</year>
<article-title>Genetic basis for clarithromycin resistance among isolates of <italic>Mycobacterium chelonae</italic> and <italic>Mycobacterium abscessus</italic></article-title>. <source>Antimicrob Agents Chemother</source>
<volume>40</volume>:<fpage>1676</fpage>&#x02013;<lpage>1681</lpage>.<pub-id pub-id-type="pmid">8807061</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nash</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Brown-Elliott</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Wallace</surname><given-names>RJ</given-names><suffix>Jr</suffix></name></person-group>
<year>2009</year>
<article-title>A novel gene, <italic>erm</italic>(41), confers inducible macrolide resistance to clinical isolates of <italic>Mycobacterium abscessus</italic> but is absent from Mycobacterium chelonae</article-title>. <source>Antimicrob Agents Chemother</source>
<volume>53</volume>:<fpage>1367</fpage>&#x02013;<lpage>1376</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.01275-08</pub-id>.<pub-id pub-id-type="pmid">19171799</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bastian</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Veziris</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Roux</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Brossier</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Gaillard</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Jarlier</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Cambau</surname><given-names>E</given-names></name></person-group>
<year>2011</year>
<article-title>Assessment of clarithromycin susceptibility in strains belonging to the <italic>Mycobacterium abscessus</italic> group by <italic>erm</italic>(41) and <italic>rrl</italic> sequencing</article-title>. <source>Antimicrob Agents Chemother</source>
<volume>55</volume>:<fpage>775</fpage>&#x02013;<lpage>781</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.00861-10</pub-id>.<pub-id pub-id-type="pmid">21135185</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rubio</surname><given-names>M</given-names></name>, <name name-style="western"><surname>March</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Garrigo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Moreno</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Espanol</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Coll</surname><given-names>P</given-names></name></person-group>
<year>2015</year>
<article-title>Inducible and acquired clarithromycin resistance in the <italic>Mycobacterium abscessus</italic> complex</article-title>. <source>PLoS One</source>
<volume>10</volume>:<elocation-id>e0140166</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0140166</pub-id>.<pub-id pub-id-type="pmid">26448181</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harada</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Akiyama</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kurashima</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Nagai</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Tsuyuguchi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Fujii</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Yano</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Shigeto</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Kuraoka</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kajiki</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kobashi</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kokubu</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Sato</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Yoshida</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Iwamoto</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Saito</surname><given-names>H</given-names></name></person-group>
<year>2012</year>
<article-title>Clinical and microbiological differences between <italic>Mycobacterium abscessus</italic> and <italic>Mycobacterium massiliense</italic> lung diseases</article-title>. <source>J Clin Microbiol</source>
<volume>50</volume>:<fpage>3556</fpage>&#x02013;<lpage>3561</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JCM.01175-12</pub-id>.<pub-id pub-id-type="pmid">22915613</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koh</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Jeon</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>NY</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Kook</surname><given-names>YH</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>SH</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>YK</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>CK</given-names></name>, <name name-style="western"><surname>Shin</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Huitt</surname><given-names>GA</given-names></name>, <name name-style="western"><surname>Daley</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Kwon</surname><given-names>OJ</given-names></name></person-group>
<year>2011</year>
<article-title>Clinical significance of differentiation of <italic>Mycobacterium massiliense</italic> from <italic>Mycobacterium abscessus</italic></article-title>. <source>Am J Respir Crit Care Med</source>
<volume>183</volume>:<fpage>405</fpage>&#x02013;<lpage>410</lpage>. doi:<pub-id pub-id-type="doi">10.1164/rccm.201003-0395OC</pub-id>.<pub-id pub-id-type="pmid">20833823</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koh</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Jeong</surname><given-names>BH</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>SY</given-names></name>, <name name-style="western"><surname>Jeon</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>KU</given-names></name>, <name name-style="western"><surname>Jhun</surname><given-names>BW</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>HY</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Huh</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Ki</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>NY</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>HK</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>YS</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>SH</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>CK</given-names></name>, <name name-style="western"><surname>Shin</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Daley</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kwon</surname><given-names>OJ</given-names></name></person-group>
<year>2017</year>
<article-title>Mycobacterial characteristics and treatment outcomes in Mycobacterium abscessus lung disease</article-title>. <source>Clin Infect Dis</source>
<volume>64</volume>:<fpage>309</fpage>&#x02013;<lpage>316</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciw724</pub-id>.<pub-id pub-id-type="pmid">28011608</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Yim</surname><given-names>JJ</given-names></name></person-group>
<year>2017</year>
<article-title>Progression and treatment outcomes of lung disease caused by <italic>Mycobacterium abscessus</italic> and <italic>Mycobacterium massiliense</italic></article-title>. <source>Clin Infect Dis</source>
<volume>64</volume>:<fpage>301</fpage>&#x02013;<lpage>308</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciw723</pub-id>.<pub-id pub-id-type="pmid">28011609</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>HY</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Kook</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yun</surname><given-names>YJ</given-names></name>, <name name-style="western"><surname>Shin</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Kook</surname><given-names>YH</given-names></name></person-group>
<year>2010</year>
<article-title><italic>Mycobacterium massiliense</italic> is differentiated from <italic>Mycobacterium abscessus</italic> and <italic>Mycobacterium bolletii</italic> by erythromycin ribosome methyltransferase gene (<italic>erm</italic>) and clarithromycin susceptibility patterns</article-title>. <source>Microbiol Immunol</source>
<volume>54</volume>:<fpage>347</fpage>&#x02013;<lpage>353</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1348-0421.2010.00221.x</pub-id>.<pub-id pub-id-type="pmid">20536733</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mougari</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Amarsy</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Veziris</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Bastian</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Brossier</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Bercot</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Raskine</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Cambau</surname><given-names>E</given-names></name></person-group>
<year>2016</year>
<article-title>Standardized interpretation of antibiotic susceptibility testing and resistance genotyping for <italic>Mycobacterium abscessus</italic> with regard to subspecies and <italic>erm</italic>41 sequevar</article-title>. <source>J Antimicrob Chemother</source>
<volume>71</volume>:<fpage>2208</fpage>&#x02013;<lpage>2212</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jac/dkw130</pub-id>.<pub-id pub-id-type="pmid">27147307</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mougari</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Bouziane</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Crockett</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Nessar</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Chau</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Veziris</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Sapriel</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Raskine</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Cambau</surname><given-names>E</given-names></name></person-group>
<year>2017</year>
<article-title>Selection of resistance to clarithromycin in <italic>Mycobacterium abscessus</italic> subspecies</article-title>. <source>Antimicrob Agents Chemother</source>
<volume>61</volume>:<elocation-id>e00943-16</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/AAC.00943-16</pub-id>.<pub-id pub-id-type="pmid">27799212</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adekambi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Berger</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Raoult</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Drancourt</surname><given-names>M</given-names></name></person-group>
<year>2006</year>
<article-title><italic>rpoB</italic> gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of <italic>Mycobacterium bolletii</italic> sp. nov., <italic>Mycobacterium phocaicum</italic> sp. nov. and <italic>Mycobacterium aubagnense</italic> sp. nov</article-title>. <source>Int J Syst Evol Microbiol</source>
<volume>56</volume>:<fpage>133</fpage>&#x02013;<lpage>143</lpage>. doi:<pub-id pub-id-type="doi">10.1099/ijs.0.63969-0</pub-id>.<pub-id pub-id-type="pmid">16403878</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonaiti</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Pesci</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Marruchella</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lapadula</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Gori</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Aliberti</surname><given-names>S</given-names></name></person-group>
<year>2015</year>
<article-title>Nontuberculous mycobacteria in noncystic fibrosis bronchiectasis</article-title>. <source>Biomed Res Int</source>
<volume>2015</volume>:<fpage>197950</fpage>. doi:<pub-id pub-id-type="doi">10.1155/2015/197950</pub-id>.<pub-id pub-id-type="pmid">26106603</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>CY</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>KP</given-names></name>, <name name-style="western"><surname>Keng</surname><given-names>LT</given-names></name>, <name name-style="western"><surname>Yen</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>HD</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>LN</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>CJ</given-names></name></person-group>
<year>2013</year>
<article-title>Factors associated with lung function decline in patients with non-tuberculous mycobacterial pulmonary disease</article-title>. <source>PLoS One</source>
<volume>8</volume>:<elocation-id>e58214</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0058214</pub-id>.<pub-id pub-id-type="pmid">23483998</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jonsson</surname><given-names>BE</given-names></name>, <name name-style="western"><surname>Gilljam</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lindblad</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ridell</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wold</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Welinder-Olsson</surname><given-names>C</given-names></name></person-group>
<year>2007</year>
<article-title>Molecular epidemiology of <italic>Mycobacterium abscessus</italic>, with focus on cystic fibrosis</article-title>. <source>J Clin Microbiol</source>
<volume>45</volume>:<fpage>1497</fpage>&#x02013;<lpage>1504</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JCM.02592-06</pub-id>.<pub-id pub-id-type="pmid">17376883</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Jing</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Yue</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Chu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name></person-group>
<year>2016</year>
<article-title>Evaluation of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of <italic>Mycobacterium abscessus</italic> subspecies according to whole-genome sequencing</article-title>. <source>J Clin Microbiol</source>
<volume>54</volume>:<fpage>2982</fpage>&#x02013;<lpage>2989</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JCM.01151-16</pub-id>.<pub-id pub-id-type="pmid">27682129</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Somerville</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Thibert</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Schwartzman</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Behr</surname><given-names>MA</given-names></name></person-group>
<year>2005</year>
<article-title>Extraction of Mycobacterium tuberculosis DNA: a question of containment</article-title>. <source>J Clin Microbiol</source>
<volume>43</volume>:<fpage>2996</fpage>&#x02013;<lpage>2997</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JCM.43.6.2996-2997.2005</pub-id>.<pub-id pub-id-type="pmid">15956443</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bankevich</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Nurk</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Antipov</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Gurevich</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Dvorkin</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kulikov</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Lesin</surname><given-names>VM</given-names></name>, <name name-style="western"><surname>Nikolenko</surname><given-names>SI</given-names></name>, <name name-style="western"><surname>Pham</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Prjibelski</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Pyshkin</surname><given-names>AV</given-names></name>, <name name-style="western"><surname>Sirotkin</surname><given-names>AV</given-names></name>, <name name-style="western"><surname>Vyahhi</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Tesler</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Alekseyev</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Pevzner</surname><given-names>PA</given-names></name></person-group>
<year>2012</year>
<article-title>SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing</article-title>. <source>J Comput Biol</source>
<volume>19</volume>:<fpage>455</fpage>&#x02013;<lpage>477</lpage>. doi:<pub-id pub-id-type="doi">10.1089/cmb.2012.0021</pub-id>.<pub-id pub-id-type="pmid">22506599</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gurevich</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Saveliev</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Vyahhi</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Tesler</surname><given-names>G</given-names></name></person-group>
<year>2013</year>
<article-title>QUAST: quality assessment tool for genome assemblies</article-title>. <source>Bioinformatics</source>
<volume>29</volume>:<fpage>1072</fpage>&#x02013;<lpage>1075</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bioinformatics/btt086</pub-id>.<pub-id pub-id-type="pmid">23422339</pub-id></mixed-citation></ref></ref-list></back></article>